Randomized, double blind, parallel group, repeat dose pharmacokinetic and pharmacodynamic study of four doses of ATL-962 (40mg, 80mg, 120mg, 240mg) in otherwise-healthy obese volunteers.
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2011
At a glance
- Drugs Cetilistat (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- 06 Sep 2006 Status change
- 04 Nov 2005 New trial record.